Radius Health Inc


  • robertward-radiusRobert (Bob) Ward is President and Chief Executive Officer of Radius. He is a global pharmaceutical industry leader managing all stages of drug development, commercialization, and strategic dealmaking and partnerships across multiple therapeutic areas. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of AstraZeneca (AZ), where he led search and evaluate activities in areas outside of AZ’s historical therapeutic focus, including orphan drugs and endocrinology. In addition, he served as Co-Chair of the Joint Development Committees in AZ’s drug development partnerships with Alcon and Galderma. After starting his career in the Molecular Biology discovery group at Genentech, Mr. Ward progressed through a series of management and executive roles with established biopharmaceutical companies including NPS Pharmaceuticals, Schering-Plough (Merck), and Bristol-Myers Squibb. Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara; an M.S. in Management from the New Jersey Institute of Technology; and an M.A. in Immunology from The Johns Hopkins University School of Medicine.

  • Gary HattersleyDr. Hattersley is Chief Scientific Officer of Radius. He has more than 20 years of experience in musculoskeletal research and is the author of numerous scientific publications related to bone biology and physiology. Prior to joining Radius, Dr. Hattersley was a Senior Scientist at Millennium Pharmaceuticals with responsibility for the discovery and development of novel small-molecule agents for the treatment of osteoporosis and other metabolic bone diseases. Dr. Hattersley also held positions at Genetics Institute/Wyeth Research investigating the application of the bone morphogenetic proteins in bone and connective tissue repair and regeneration. Dr. Hattersley received a PhD in Experimental Pathology from St. George's Hospital Medical School in London.
  • David SnowDavid Snow is Chief Commercial Officer for Radius Health. He has more than 25 years of experience in the global commercialization of brands across numerous therapy areas and geographies. Most recently, Mr. Snow was President of AstraZeneca’s China business and during his tenure AZ China experienced rapid growth becoming AZ’s second largest business behind the US. In his fifteen years with AstraZeneca he served in a variety of leadership roles including leading the US Cornerstone business unit responsible for $10B in annual sales across several therapeutic areas including oncology. He was also the first global commercialization Vice President for Brilinta and head of US Commercial Operations. Before joining AZ, Mr. Snow held numerous global and US commercial leadership roles for Bristol-Myers Squibb, Searle and Hoechst-Roussel respectively. He served on the RDPAC industry association board in China for several years. Mr. Snow received his BS in Business Administration from Auburn University, and an MBA from New York University - Leonard N. Stern School of Business
  • Dinesh Purandare Dinesh Purandare is Senior Vice President and Head of Global Oncology. Dinesh has over 20 years of experience in the pharmaceutical industry out of which 15 years have been in global oncology where he served in leadership positions in various companies around the world. Dinesh is a experienced and respected leader and brings a unique blend of strong commercial, market access and development expertise in multiple tumor types like Breast, Colorectal, Renal, Prostate and Hematology.

    Prior to joining Radius, Dinesh spent 5 years at Sanofi Oncology, initially as Vice President and Head of Marketing and later as Vice President and Project Head where he was instrumental in building and leading the commercial and development activities culminating in a successful launch of Jevtana (Cabazitaxel) and approval of Zaltrap (aflibercept) in several countries around the world including the US and EU. He also co-chaired the Joint Development Committee (Oncology) of Sanofi and Regeneron Pharmaceuticals and was a member of the Oncology Management Team (OMT). Prior to Sanofi, Dinesh served as VP and Head of Oncology Center of Excellence at GSK Headquarters in the UK and held other senior positions at Pharmacia /Pfizer and Farmitalia Carlo Erba (Milan, Italy).

    Dinesh pursued his studies in Business Management at the University of Bombay where he also received a degree in Organic Chemistry. Dinesh also received a Diploma in Advanced Marketing Management from the Chartered Institute of Marketing, UK and has attended numerous programs at European School of Oncology and executive programs at Kellogg School of Management, Evanston, IL.

  • Greg WilliamsDr. Williams is Chief Development Officer of Radius. He is a pharmaceutical industry and drug development veteran with more than 30 years of experience leading new product development, regulatory affairs, lifecycle management and commercialization for both small biotechnology and large pharmaceutical companies. Prior to joining Radius, Dr. Williams was Vice President of Regulatory Affairs, Global Product and Clinical Development, and Program Management with The Medicines Company, where he led the successful NDA and MAA filings of the IV antihypertensive drug Cleviprex®. Earlier positions include Vice President of Regulatory Affairs, Regulatory Compliance and Program Management for NPS Pharmaceuticals, where he led the successful MAA filing of the osteoporosis drug Preotact™. He has also held various management positions in clinical and drug product development for Yamanouchi Pharma America, Theraport Biosciences, GlaxoSmithKline Consumer Healthcare, and Parke-Davis Pharmaceutical. Dr. Williams has a Ph.D. in Biopharmaceutics from Rutgers University and an MBA from Cornell University.
  • Lorraine FitzpatrickDr. Fitzpatrick is Chief Medical Officer of Radius Health. Previously, Dr. Fitzpatrick was the Medicine Development Leader at GlaxoSmithKline for Denosumab, where she led an international team representing multiple disciplines including clinical development, regulatory, manufacturing, commercial, operations, epidemiology, and global health outcomes. Prior to that, Dr. Fitzpatrick was Group Director at GlaxoSmithKline, where she led the clinical development of novel agents to treat musculoskeletal diseases and women's health.

    Dr. Fitzpatrick has held many national and international positions including Executive Director at Amgen where she worked in the field of osteoporosis and oncology. She has served as Chair of the GCRC study section of NCRR, NIH; Advocacy Committee of the American Society of Bone and Mineral Research (ASBMR); Chair of Public Communications Committee and the Media Relations Steering Committee of The Endocrine Society (TES). She has been a member of the Publications Committee of the ASBMR and TES and of the Advisory Committee for the Office of Research on Women's Health at NIH. Dr. Fitzpatrick has served on the NCQA Technical Subgroup on Osteoporosis, the Clinical Guidelines Committee of The Endocrine Society, the Scientific Program Committees of NAMS and the ASBMR, Associate Editor for The Mayo Clinic Proceedings and the AMA Scientific Advisory Board: Osteoporosis Guidelines. She has received numerous honors and awards including the Boy Frame Award of the ASBMR, the Glenn Foundation Award in Endocrinology and Aging from The Endocrine Society, and election to the American Society of Clinical Investigation. Dr. Fitzpatrick has published extensively in the field of mineral metabolism.

    Dr. Lorraine A. Fitzpatrick completed her undergraduate education at Wellesley College with honors in Molecular Biology. She graduated from the Pritzker school of Medicine at the University of Chicago and completed her residency training in Internal Medicine at Columbia-Presbyterian Medical Center in New York. Dr. Fitzpatrick trained in Mineral Metabolism and Endocrinology at the National Institute of Diabetes, Digestive, Arthritis and Kidney Disorders at the National Institutes of Health. She joined the staff as Chief of Endocrine at the Audie Murphy VA hospital and Assistant Professor of Medicine at the University of Texas Health Science Center in San Antonio, TX. Dr. Fitzpatrick joined the staff at the Mayo Clinic and rose to the rank of Professor of Medicine. At Mayo, she was Director of Bone Histomorphometry and Director of the Women's Health Fellowship, the latter which she founded.

  • Nick HarveyNick Harvey is Senior Vice President and Chief Financial Officer of Radius. He has more than 15 years of experience in building and financing life sciences and technology companies. Prior to joining Radius, he served for four years as Managing Director of Shiprock Capital, a venture capital firm, where he was responsible for deal-sourcing, negotiating and closing transactions, and developing strategic plans for portfolio companies. Before that, Mr. Harvey served as CFO of a number of venture-backed companies over a 10-year period, including Transfusion Technologies and Transcend Therapeutics. At Transfusion, he helped to close a major distribution agreement with Zimmer and oversaw the company's acquisition by Haemonetics. Mr. Harvey holds an undergraduate degree in Economics and a law degree with first-class honors from the Australian National University, and an MBA from the Harvard Business School.

  • Brent Hatzis-SchochBrent Hatzis-Schoch is Senior Vice President and General Counsel of Radius. He has more than 20 years of experience in leadership positions in the global pharmaceutical and biotechnology industry with both commercial and development stage companies. Prior to joining Radius, Mr. Hatzis-Schoch was Senior Vice President and Chief Legal Counsel of Merz Pharma in Frankfurt, Germany, where he had global responsibility for the legal, intellectual property and compliance functions. Prior to Merz, Mr. Hatzis-Schoch served as General Counsel to Agennix AG, a publicly-traded development stage biopharmaceutical company. He began his legal career in private practice and later held senior legal positions in the U.S. and internationally, including as European legal counsel for Baxter International, Associate General Counsel of Pharmacia Corporation, and General Counsel of GPC Biotech AG. Mr. Hatzis-Schoch holds a J.D. from George Washington University and a B.A. from the University of Delaware.
  • Lauren GallagherLauren Gallagher is Vice President of Finance at Radius. She has more than 10 years of accounting and finance experience. Prior to joining Radius, she served as Director of External Reporting at American Tower Corporation, a leading global owner, operator and developer of wireless and broadcast communications real estate, where she was responsible for building and leading the company’s reporting function and for a wide range of activities including financial statement preparation, SEC filings and technical accounting. Before that, Ms. Gallagher provided accounting and consulting services to clients in a variety of industries, including financial services, IT consulting, telecommunications, retail, manufacturing, and technology. Ms. Gallagher began her career as an auditor for KPMG, where she planned and administered audit engagements for several large public companies. Ms. Gallagher holds a B.S. in Accounting and a Master of Science in Accounting from the University of Massachusetts at Amherst. Ms. Gallagher is also a Certified Public Accountant.
  • Geoffrey A. SwireGeoff Swire is Vice President of Business Development & Strategy of Radius. He has more than 15 years of experience leading development and commercial teams to build successful biopharmaceutical businesses. Prior to joining Radius, he served as Vice President, Global Commercial Operations in Genzyme’s Transplant & Oncology business unit, where he was responsible for leading the global integration of three hematology brands from Bayer HealthCare in over 90 markets. Earlier at Genzyme, as head of program management for the Transplant business unit, he established and directed the search and evaluation team that brought in Mozobil through the acquisition of AnorMED and led development teams responsible for major NDA/MAA submissions. Before that, Mr. Swire led transformational initiatives for global pharmaceutical companies as a senior manager in Accenture’s Health & Life Sciences strategy consulting practice. Mr. Swire holds a B.A. from Dartmouth College and an M.P.P. concentrating on financial markets and analysis from Harvard University.